Cargando…
Systems biology approaches based discovery of a small molecule inhibitor targeting both c-Met/PARP-1 and inducing cell death in breast cancer
Breast cancer is the second most common types of cancer worldwide. Molecular strategies have developed rapidly; however, novel treatments strategies with high efficacy and lower toxicity are still urgently demanded. Notably, biological networks estimated from microarray data and functional activity...
Autores principales: | Yu, Tian, Cheng, Lijia, Yan, Xueling, Xiong, Hang, Chen, Jie, He, Gang, Zhou, Hui, Dong, Hongbo, Xu, Guangya, Tang, Yong, Shi, Zheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065998/ https://www.ncbi.nlm.nih.gov/pubmed/32201536 http://dx.doi.org/10.7150/jca.40758 |
Ejemplares similares
-
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
por: Du, Yi, et al.
Publicado: (2016) -
Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition
por: D’Ambrosio, Concetta, et al.
Publicado: (2022) -
Inhibition of c‐MET increases the antitumour activity of PARP inhibitors in gastric cancer models
por: Koustas, Evangelos, et al.
Publicado: (2020) -
PARP14 is a PARP with both ADP-ribosyl transferase and hydrolase activities
por: Đukić, Nina, et al.
Publicado: (2023) -
In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer
por: Lin, Z. Ping, et al.
Publicado: (2021)